Christian Meyer
Operationeel Directeur bij VectivBio AG
Profiel
Christian Meyer is currently the Chief Operating Officer at VectivBio Holding AG since 2021.
He is also currently the Chief Operating Officer at VectivBio AG.
Previously, he held the position of Principal at Novo Nordisk A.
From 2006 to 2010, he worked at Symphogen A as the VP-Clinical Research, Medical & Regulatory Affairs.
During the same period, he was also the Chief Medical Officer at RSPR Pharma AB.
From 2013 to 2017, he served as the Chief Medical Officer at uniQure NV.
From 2017 to 2019, he held the position of Chief Medical Officer at Therachon Holding GmbH.
Additionally, he is the Chief Development Officer at Therachon AG.
Dr. Meyer obtained his doctorate degree from the University of Copenhagen.
Actieve functies van Christian Meyer
| Bedrijven | Functie | Begin |
|---|---|---|
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Operationeel Directeur | - |
Eerdere bekende functies van Christian Meyer
| Bedrijven | Functie | Einde |
|---|---|---|
Therachon Holding GmbH
 Therachon Holding GmbH BiotechnologyHealth Technology Therachon Holding GmbH engages in the acquisition, management, financing, and disposal of participating interests in firms. It also acquires, holds, and disposes intellectual property rights. The company was founded on December 22, 2015 and is headquartered in Basel, Switzerland. | Hoofd Techniek/Wetenschap/O&O | 01-06-2019 |
| UNIQURE N.V. | Hoofd Techniek/Wetenschap/O&O | 01-11-2017 |
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Hoofd Techniek/Wetenschap/O&O | 01-01-2010 |
| Therachon AG | Corporate Officer/Principal | - |
| VECTIVBIO HOLDING AG | Operationeel Directeur | - |
Opleiding van Christian Meyer
| University of Copenhagen | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| NOVO NORDISK A/S | Health Technology |
| UNIQURE N.V. | Health Technology |
| Bedrijven in privébezit | 6 |
|---|---|
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Health Technology |
RSPR Pharma AB
 RSPR Pharma AB Pharmaceuticals: MajorHealth Technology RSPR Pharma AB develops therapeutics for inflammatory vascular diseases. The firm's products are used to treat diseases such as atherosclerosis and abdominal aortic aneurysm. The company was founded by Carl-Johan Dalsgaard in 2006 and is headquartered in Stockholm, Sweden. | Health Technology |
VectivBio Holding AG
 VectivBio Holding AG Pharmaceuticals: MajorHealth Technology VectivBio Holding AG is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of treatments for severe rare conditions with significant unmet medical need. It operates through Switzerland, Canada, and the United States geographical segment. The company was founded by Luca Santarelli on May 22, 2019 and is headquartered in Basel, Switzerland. | Health Technology |
Therachon Holding GmbH
Therachon Holding GmbH BiotechnologyHealth Technology Therachon Holding GmbH engages in the acquisition, management, financing, and disposal of participating interests in firms. It also acquires, holds, and disposes intellectual property rights. The company was founded on December 22, 2015 and is headquartered in Basel, Switzerland. | Health Technology |
| Therachon AG | |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Health Technology |
